Corneal cross-linking

Corneal cross-linking
Cross-linking procedure, UV light source[1]
Other namesCross-linking, CXL, C3-R, CCL, KXL
CPT0402T

Corneal cross-linking (CXL) with riboflavin (vitamin B2) and UV-A light is a surgical treatment for corneal ectasia such as keratoconus, PMD, and post-LASIK ectasia.

It is used in an attempt to make the cornea stronger. According to a 2015 Cochrane review, there is insufficient evidence to determine if it is useful in keratoconus.[2] In 2016, the US Food and Drug Administration approved riboflavin ophthalmic solution crosslinking based on three 12-month clinical trials.[3]

  1. ^ Renesto Ada, C; Sartori, M; Campos, M (January–February 2011). "[Cross-linking and intrastromal corneal ring segment]". Arquivos Brasileiros de Oftalmologia. 74 (1): 67–74. doi:10.1590/s0004-27492011000100017. PMID 21670914.
  2. ^ Cite error: The named reference Syk2015 was invoked but never defined (see the help page).
  3. ^ Lowes, Robert (18 April 2016). "FDA Approves Photrexa for Corneal Crosslinking in Keratoconus". Medscape.com.